References
- Verma D, Kantarjian H, Jain N, Cortes J. Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukaemia not previously exposed to interferon alpha. Leuk Lymph 2008; 49: 1399–1402
- Branford S, Seymour J F, Grigg A, Arthur C, Rudzki Z, Lynch K, et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007; 13: 7080–7085
- Lange T, Bumm T, Mueller M, Otto S, Al-Ali H K, Grommisch L, et al. Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation. Leukemia 2005; 19: 1262–1265
- Michor F, Hughes T P, Iwasa Y, Branford S, Shah N P, Sawyers C L, et al. Dynamics of chronic myeloid leukaemia. Nature 2005; 435: 1267–1270
- Roeder I, Horn M, Glauche I, Hochhaus A, Mueller M C, Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 2006; 12: 1181–1184
- Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999; 94: 2056–2064
- Rousselot P, Huguet F, Rea D, Legros L, Cayuela J M, Maarek O, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58–60